Abbvie, AOP-Orphan, Camurus, GL Pharma, Ferrer, Harm reduction … · 2019. 12. 6. · Abbvie,...
Transcript of Abbvie, AOP-Orphan, Camurus, GL Pharma, Ferrer, Harm reduction … · 2019. 12. 6. · Abbvie,...
06.12.2019
1
Univ. Prof. Dr. Gabriele Fischer
Center of Public Health
Department of Psychiatry & Psychotherapy
Harm reduction in drug addiction with special emphasis on women
OPCAT Commission 3
Disclosure
Funding received over the past 10 years from
Abbvie, AOP-Orphan, Camurus, GL Pharma, Ferrer, Gilead, Indivior, Mundipharma, Lundbeck, Pfizer, Reckitt Benckiser (honorarium for travel expenses & delivery of speeches)
In 2010, mental and substance use disorders constitutedfor10.4% of the global burden of disease
� leading cause of years lived with disability among all disease groups
� the global direct and indirect economic costs of mental disorders are estimated at
US $ 2.5 trillion (years 2010)
� indirect costs (US $ 1.7 trillion) are much higher than the direct costs (US$0.8 trillion)
Mental disorders therefore account for more economic costs thanchronic somaticdiseasessuch ascanceror diabetes
The economic costs of mental disorders
A. Direct and indirect costs
B. Impact on economic growth
C. Value of statistical life
Trautmann et al., 2016, EMBO reports
06.12.2019
2
Economic burden
• Substance use disorders: €66 billion/year1
– €28 billion direct health-related costs
– €14 billion direct non-medical costs (expenses associated with the
delivery of health care & health services, e.g. transportation)
– €24 billion indirect costs (e.g., unemployment)
� WITHOUT costs related to criminality/justice system
Pharm. Treatment of opioid dependence: € 3.800 per patient/year
Costs per person/year in prison: €34.5002
�High societal costs not only caused by the severity of addictive
disorders but also by their close relation to criminal behaviour
1 Olesen et al. (2012). European Journal of Neurlogy 19(1): 155-162; 2 Metz et al. (2012b). Therapie statt Strafe. Gesundheitsbezogene Maßnahmen bei Substanzabhängigkeit und Suchtmittel(straf)recht. Vienna, Austria: NWV
Gender/sex differencesin addiction
• prevalence/incidence• age of onset• treatment access• comorbidity• consumption patterns• metabolism• secondary damage• mortality• abstinence behaviour
Men & Women are different
In addition also
� cultural background, ethnicity and economics play a major role
In the spectrum of medical diseases women do have a higher retention rate in all disorders, but not in substance use disorder - related to limited access to treatment.
06.12.2019
3
Wittchen et al, 2005.
Sex and mood disorders: prevalence
06.12.2019
4
Prevalence of psychiatric symptoms (n=174 pregnant women with substance use disorder)
Benningfield, M.M., Arria, A.M., Kaltenbach, K., Heil, S.H., Stine, S.M., Coyle, M.G., Fischer, G., Jones, H.E., Martin, P.R. Co-occurring Psychiatric Symptoms are Associated with Increased Psychological, Social & Medical Impairment in Opioid Dependent Pregnant Women. AM J Addict, 2010, 19(5): 416-421.
Psychiatric Symptoms In %
One or more psychiatric diagnosis 65
Major Depression (MDD) 32
Dysthymia 31
Hypomanic episode 39
Anxiety disorders
- Generalized anxiety disorder (GAD) 40
- Panic disorder 26
- Agoraphobia 22
Social Phobia 16
Post-traumatic Stress Disorder (PTSP) 16
Obsessive–compulsive disorder (OCD) 3
Bulimia <1
Symtoms at some point in the past 30 days
in %
Mood symptoms 49
Anxiety symptoms 40
Suicial thinking 13
Treatment
is a human right & not a priviledge
Human Rights Treaties - UN Principles
Convention on Elimination of Discrimination against Women
(CEDAW)
Covenant on Economic & Social & Cultural Rights (CE SCR)
Covenant on Civil & Political Rights (CCPR)
Universal Declaration of Human Rights (UDHR)
Convention on Elimination of
Racial Discrimination
(CERD)
Convention on the Rights of Persons with Disabilities
(CRPD)
Convention Against Torture (CAT)
“Bill of Rights”
06.12.2019
5
Convention on the Rights of Persons with Disabilities (CRPD)Quelle: United Nations. Abgerufen von https://www.un.org/development/desa/disabilities/convention-on-the-rights-of-persons-with-
disabilities.htmlam 13.3.2017 um 18:00.
Convention on the Rights of Persons with Disabilities(Art 1 CRPD)
Persons with disabilities include those who have long-term physical, mental*, intellectual or sensory impairments which in interaction with various barriers may hinder their full and effective participation in society on an equal basis with others.
*This includes of course: substance use disorder
= chronic relapsing psychiatric disorder
Obligation to ensure participation: Art 4/3 CRPD
In the development and implementation of legislation and policies to implement the present Convention and in other decision-making processes concerning issues relating to persons with disabilities,
States Parties shall closely consult with and actively involve persons with disabilities, including children with disabilities, through their representative organizations.
19
Right to Health – Article 12 CESCR1. The States Parties to the present Covenant recognize the right of everyone to the enjoyment of the highest attainable standard of physical and mental health.
Benefits of Scientific Progress – Article 15 CESCR The States Parties to the present Covenant recognize the right of everyone:
(b) To enjoy the benefits of scientific progress and its applications (eg: positive discrimination – women as more marginalized group should benefit early & comprehensively on new medical options)
20
Covenant on Economic, Social and Cultural Rights (CESCR)
06.12.2019
6
Pregnant women with substance use disorders
Ethical & legal guidelines
Convention on the Elimination of All Forms of Discrimination Against Women
(Right to Health – Article 12 CEDAW)
• States Parties shall take all appropriate measures to eliminate discrimination against women in the field of health care in order to ensure, on a basis of equality of men and women, access to health care services, including those related to family planning.
• (..) States Parties shall ensure to women appropriate services in connection with pregnancy, confinement and the post-natal period, granting free services where necessary, as well as adequate nutrition during pregnancy and lactation.
The Human Right for a reproductive Health
The rights of women “include their right to have control over and decide freely and responsibly on matters related to their sexuality, including sexual and reproductive health, free of coercion, discrimination and violence. http://www.ohchr.org/Documents/Issues/Women/WRGS/SexualHealth/INFO_Contra_FamPlan_WEB.pdf
Past month substance use among pregnant women 2018, US data
2018 National Survey on Drug Use and Health, SAMHSA
06.12.2019
7
Abused Prescription Opioids
Oxycodone (OxyContinR) Aspirin & Oxycodone (PercodanR)
Hydromorphone (DilaudidR, PalladoneR)Codeine
Tramadol
Fentanyl
ISC1
Best interest of the child (Art 3 Child Rights Convention)
1. Right
2. Legal principle
3. Procedural rule
Ad 1: Must be determined on a case-by-case basis
Ad 2: Resolve any conflicts with other human rights treaties (eg under consideration ESCR; CRPD..)
Ad 3: Attention must be paid to all solutions, which are in the child’s best interests (eg full information & disclosure to parents, including information on diagnosis & course of treatment)
Child Rights Convention -Determination of the child’s best interests:
Protection of the family has to be ensured (Right to Privacy, European Convention Human Rights-ECHR)
• Support for parents to fulfill their parental responsibilities
• Economic reasons no justification for separation (Art 10 ESCR)
• Child’s life and development have to be considered holistically
• Future consequences of decision have to be taken into account
• Decision making has to be fair & give due respect to parents’ views
• Non-discrimination: eg regarding health-status, social origin etc.
Slide 25
ISC1 Dear Prof Fischer, we have added Tramadol, Codeine and Fentanyl and we re-arranged the layout slightly to accomodate the extra text. Please let us know if you are happy with this.Isabella SS. Cruz, 21/06/2017
06.12.2019
8
Human rights consideration in regard:opioid dependent/maintained pregnant
women & neonatesIn some countries/institutions women are forced to withdraw from methadone/burprenorphine during pregnancy:
• no scientific evidence in favour of forced withdrawal during pregnancy-contrary - “quasi-voluntary“: increased risk of mortality & morbidity
• sometimes institutions follow even an extortive approach: women have to “show treatment motivation” to be entitled to care for their child
� Practices against scientific evidence are not in line with the right of highest standard of care and the right of scientific progress .. � “methadone/buprenorphine maintenance” etc.
� See:The States Parties to the present Covenant recognize the right of everyone (…) to enjoy the benefits of scientific progress and its applications (…)1.
� Forced withdrawal during pregnancy could even lead to harm of the unborn child due to physical and psychological stress of the mother
1 Article 15, International Covenant on Economic, Social and Cultural Rights
Human rights concerns- examples
During the postpartal period, some institutions do not inform mothers about medication and diagnostic procedures concerning their new born. This is
seen critically, as the legal guardian has the right to full information about therapy and examinations concerning the child in order to give informed
consent.
� Implementation of the right to health1 must take into account all human rights principles, especially the guiding principles of the Convention, and must be shaped by evidence-based public health standards and best practices.2
� It is essential that supportive policies are in place and that children, parents and health workers have adequate rights-based guidance on consent, assent and confidentiality.2
1 Article 24, Child Rights Convention2 General Comment 15, Child Rights Committee, Right to Health
Sample: 8509 Boston Birth Cohort mother-newborn pairs for p renatal and perinatal analyses
- Overall, 454 of the 8509 children (5.3%) had in utero opioid exposure.
At birth, opioid exposure was associated
- with higher risks of fetal growth restriction (odds ratio [OR], 1.87; 95%CI, 1.41-2.47)
- Preterm birth (OR, 1.49; 95%CI, 1.19-1.86)
Sample: cont`d
Opioid exposure was associated with
- increased risks of lack of expected physiological development (OR, 1.80; 95%CI, 1.17-2.79)
- conduct disorder/emotional disturbance (OR, 2.13; 95%CI, 1.20-3.77) among preschool-aged children.
In school-aged children, opioid exposure was associ ated with
- a higher risk of attention-deficit/hyperactivity disorder (OR,2.55; 95%CI, 1.42-4.57)
06.12.2019
9
Costs of preterm deliveries in UK in €/ infant
Preterm delivery
(< 37 weeks)
Early preterm delivery
(< 33 weeks)
Very early preterm delivery
(< 28 weeks)
Prevalence of live births 7.17 1.71 0.48
Costs for delivery 443,- 974,- 2.425,-
Costs for neonatal care 28.993,- 79.447,- 116.230,-
Costs for inpatient treatment until age of 18 yrs 29.762,- 81.152,- 120.495,-
Costs for outpatient treatment until age of 18 yrs 761,- 1.104,- 2.187,-
Costs for medical and social care until age of 18 yrs
30.775,- 83.015,- 124.913,-
TOTAL 90.734,- 245.692,- 466.250,-
Mangham et al. 2009. The Cost of Preterm Birth Throughout Childhood in England and Wales. Pediatrics 123: e312-327
• Global prevalence of alcohol use during pregnancy:
9.8% (95% CI 8·9–11·1)
• Estimated prevalence of fetal alcohol syndrome (FAS) in thegeneral population: 14.6/10 000 people (95% CI 9·4–23·3)
� one in every 67 women who consumed alcohol during pregnancy delivers
a child with FAS
� 119 000 children born with FAS in the world every year
Health system costs of Fetal Alcohol Syndrome (US)
Mean costsper year(US$)
Additionalcosts per year
* (US$)
Potential cumulative savings per case and year (US$)
After 10 years After 20 years
FAS 2.842 2.342 128.810 491.820
ADHD 649 154 8.470 32.340
Learning disability 1.302 806 44.330 169.260
Developmentaldisorder
2.286 1.797 98.835 377.370
ODD** 1.377 883 48.565 185.430
Epileptic seizures 2.181 1.689 92.895 345.690
Health system costs of FAS and comorbid disorders (U S) until 21 years of age
*Additional costs: Costs of a child with the disorder minus costs of a child without the disorder**Opositional Defiant Disorder
Klug, M. G., & Burd, L. (2003). Neurotoxicology and teratology, 25(6), 763-765.
Thank you for your attention!
36